Research ExplorerPublicationsDabrafenib plus trametinib versus anti-PD-1 monotherapy as a...

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

  • Xue Bai
  • Ahmed Shaheen
  • Charlotte Grieco
  • Paolo D d'Arienzo
  • Florentia Mina
  • Juliane A Czapla
  • Aleigha R Lawless
  • Eleonora Bongiovanni
  • Umberto Santaniello
  • Helena Zappi
  • Dominika Dulak
  • Andrew Williamson
  • Rebecca Lee
  • Avinash Gupta
  • Caili Li
  • Lu Si
  • Martina Ubaldi
  • Naoya Yamazaki
  • Dai Ogata
  • Rebecca Johnson
  • Benjamin C Park
  • Seungyeon Jung
  • Gabriele Madonna
  • Juliane Hochherz
  • Yoshiyasu Umeda
  • Yasuhiro Nakamura
  • Christoffer Gebhardt
  • Lucia Festino
  • Mariaelena Capone
  • Paolo Antonio Ascierto
  • Douglas B Johnson
  • Serigne N Lo
  • Georgina V Long
  • Alexander M Menzies
  • Kenjiro Namikawa
  • Mario Mandala
  • Jun Guo
  • Paul Lorigan
  • Yana G Najjar
  • Andrew Haydon
  • Pietro Quaglino
  • Genevieve M Boland
  • Ryan J Sullivan
  • Andrew J S Furness
  • Ruth Plummer
  • Keith T Flaherty

Related Research units

Bibliographical data

Original languageEnglish
ISSN2589-5370
DOIs
Publication statusPublished - 05.2024
PubMed 38572079